Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Phase 1

Active, not recruiting

Conditions: Rhabdoid Tumor
Solid Tumors
Medulloblastoma
Ewing Sarcoma
Rhabdomyosarcoma
Diffuse Intrinsic Pontine Glioma
Neuroblastoma

Interventions: Drug: Palbociclib
Drug: Temozolomide
Drug: Cyclophosphamide
Drug: Irinotecan
Drug: Topotecan

First Posted Date: 2018-10-17

Last Posted Date: 2025-01-14

Lead Sponsor: Pfizer

Target Recruit Count: 128

Registration Number: NCT03709680

Locations: 🇸🇰
Detska fakultna nemocnica s poliklinikou Banska Bystrica, Banska Bystrica, Slovakia
🇺🇸
University of Alabama at Birmingham/Children's of Alabama, Birmingham, Alabama, United States
🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States

and more 95 locations

Rheumatoid Arthritis Satisfaction Outcome Research

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2018-10-12

Last Posted Date: 2021-03-16

Lead Sponsor: Pfizer

Target Recruit Count: 421

Registration Number: NCT03703817

Locations: 🇰🇷
Kyung Hee University Hospital at Gangdong / Rheumatology, Seoul, Gangdong-gu, Korea, Republic of
🇰🇷
Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of
🇰🇷
Wonkwang University Hospital / Division of Rheumatology, Iksan, Jeonlabuk-do, Korea, Republic of

and more 20 locations

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Breast Neoplasms
Colorectal Neoplasms
Carcinoma, Renal Cell
Prostate Neoplasms
Neoplasms, Squamous Cell
Melanoma
Liver Neoplasms
Mesothelioma
Pancreatic Neoplasms

Interventions: Drug: PF-06952229
Drug: Enzalutamide

First Posted Date: 2018-09-26

Last Posted Date: 2024-06-26

Lead Sponsor: Pfizer

Target Recruit Count: 49

Registration Number: NCT03685591

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
The Sarah Cannon Research Institute / Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

and more 12 locations

A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients

Phase 4

Completed

Conditions: Leukemia
Precursor b-Cell Lymphoblastic Leukemia-Lymphoma
ACUTE LYMPHOBLASTIC LEUKEMIA

Interventions: Drug: inotuzumab ozogamicin-dose level 2
Drug: Inotuzumab ozogamicin-dose level 1

First Posted Date: 2018-09-19

Last Posted Date: 2023-11-22

Lead Sponsor: Pfizer

Target Recruit Count: 102

Registration Number: NCT03677596

Locations: 🇮🇳
Sahyadri Clinical Research and Development Centre, Pune, Maharashtra, India
🇺🇸
LAC+USC Medical Center, Los Angeles, California, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 41 locations

Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC

Phase 1

Terminated

Conditions: Triple-negative Breast Cancer
Non-Small Cell Lung Cancer

Interventions: Biological: PF-06936308

First Posted Date: 2018-09-18

Last Posted Date: 2024-08-23

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT03674827

Locations: 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸
University of Utah, Huntsman Cancer Hospital, Salt Lake City, Utah, United States

and more 31 locations

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

Phase 4

Terminated

Conditions: ALK or ROS1-positive NSCLC

Interventions: Drug: Crizotinib

First Posted Date: 2018-09-14

Last Posted Date: 2024-11-08

Lead Sponsor: Pfizer

Target Recruit Count: 41

Registration Number: NCT03672643

Locations: 🇨🇳
Eastern Theater General Hospital ,QinHuai District Medical Area, Nanjing, Jiangsu, China
🇨🇳
Jilin Province Cancer Hospital, Changchun, Jilin, China
🇨🇳
Sichuan Province Cancer Hospital, Chengdu, Sichuan, China

and more 10 locations

A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects

Phase 1

Completed

Conditions: Healthy Females

Interventions: Drug: PF-04965842
Drug: Ethinyl estradiol (EE) and levonorgestrel (LN)

First Posted Date: 2018-09-07

Last Posted Date: 2020-03-23

Lead Sponsor: Pfizer

Target Recruit Count: 17

Registration Number: NCT03662516

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Phase I Safety, Pharmacokinetics and Bioavailability Study Comparing Rate and Extent of Absorption of Two Different Forms of Tafamidis (PF-6291826)

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Tafamidis

First Posted Date: 2018-09-07

Last Posted Date: 2019-02-11

Lead Sponsor: Pfizer

Target Recruit Count: 9

Registration Number: NCT03662191

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

A Renal Impairment Study for PF-04965842

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: PF-04965842

First Posted Date: 2018-09-06

Last Posted Date: 2022-03-22

Lead Sponsor: Pfizer

Target Recruit Count: 23

Registration Number: NCT03660241

Locations: 🇺🇸
University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
University of Miami Division of Clinical Pharmacology, Miami, Florida, United States

and more 1 locations

A Study to Evaluate the PF-06700841 Effect on QTc Interval in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-06700841
Drug: Placebo
Drug: moxifloxacin

First Posted Date: 2018-09-04

Last Posted Date: 2019-02-27

Lead Sponsor: Pfizer

Target Recruit Count: 33

Registration Number: NCT03656952

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy